Share This Page
Litigation Details for Advanced Accelerator Applications USA, Inc. v. Curium US LLC (D. Del. 2025)
✉ Email this page to a colleague
Advanced Accelerator Applications USA, Inc. v. Curium US LLC (D. Del. 2025)
| Docket | 1:25-cv-01156 | Date Filed | 2025-09-16 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | Assigned To | Unassigned Judge | |
| Jury Demand | Referred To | ||
| Patents | 10,596,276; 10,596,278; 11,904,027; 12,415,003 | ||
| Firms | Business Litigation | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Advanced Accelerator Applications USA, Inc. v. Curium US LLC
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Advanced Accelerator Applications USA, Inc. v. Curium US LLC (D. Del. 2025)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2025-09-16 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: Advanced Accelerator Applications USA, Inc. v. Curium US LLC (D. Del. 2025)
Last updated: June 17, 2026
Advanced Accelerator Applications USA, Inc. v. Curium US LLC (1:25-cv-01156): litigation summary, patent issues, and business risk
Advanced Accelerator Applications USA, Inc. v. Curium US LLC (D. Del., Case No. 1:25-cv-01156) is a recently filed federal patent dispute. No docket-accessible complaint text, asserted patent numbers, infringement theories, or requested relief are provided in the available record here. Without those litigation specifics, a complete litigation summary and patent-by-patent analysis cannot be produced.
What is the procedural posture of Advanced Accelerator Applications v. Curium US (1:25-cv-01156)?
Answer: Unknown from the provided inputs. A litigation summary requires at minimum: filing date, venue docket entries, whether a preliminary injunction is sought, and whether the case centers on Paragraph IV (or other) FDA notice-based claims.
Case facts that are missing for a litigation-grade summary
- Complaint filing date and parties as named in the caption
- Whether the complaint asserts U.S. patents in the Orange Book for a specific FDA NDA/BLA/ANDA product
- Whether Curium filed an ANDA or relied on a listed reference product (and which one)
- Whether the asserted claims cover radioisotope drug product composition, radiolabeling, dosing regimen, manufacturing, or methods of use
- Whether Curium is described as an ANDA applicant, label filer, or commercial entrant
- Docket outcomes to date (motions to dismiss, answers, claim construction, scheduling order)
What patents protect Advanced Accelerator Applications’ product in the Curium US dispute?
Answer: Not determinable from the available record here.
What must be identified to answer this question correctly
- Asserted U.S. patent publication/application numbers and claim numbers
- Patent assignees and current owners
- Whether patents are product, formulation, process, or method-of-use
- Whether non-infringement and invalidity theories are pled (anticipation, obviousness, indefiniteness, enablement, written description, inequitable conduct)
Is this case a Paragraph IV ANDA challenge, a 505(b)(2) dispute, or a different IP theory?
Answer: Not determinable from the available record here.
Why this classification matters
- Paragraph IV cases drive automatic statutory timelines, typical remedies, and early-case procedural patterns
- Non-Orange-Book product IP disputes often proceed on different schedules and claim sets (trade secrets, method claims, manufacturing IP, or contract-based rights)
When does the Advanced Accelerator Applications patent estate expire, and what exclusivity windows are at stake?
Answer: Not computable from the provided inputs.
Patent and exclusivity milestones needed
- Earliest and latest U.S. utility patent expiration dates for the asserted patents
- Patent term adjustment and patent term extension (if any)
- Relevant FDA exclusivities (NCE, BLA interchangeability, pediatric, 505(b)(2) exclusivity, data exclusivity)
- Whether any asserted patents are subject to terminal disclaimers that shorten term
What remedies is Advanced Accelerator Applications seeking against Curium US?
Answer: Not determinable from the available record here.
Remedy categories that commonly appear in these disputes
- Permanent injunction under 35 U.S.C. § 283
- Preliminary injunction under 35 U.S.C. § 283/Rule 65
- Monetary damages (reasonable royalty and/or lost profits)
- Enhanced damages for willfulness under 35 U.S.C. § 284
- Attorneys’ fees under § 285
- Declaratory relief as to non-infringement/invalidity counterclaims
How strong is the patent infringement and validity case for each side?
Answer: Cannot be evaluated without:
- asserted claims
- accused product identification (radioisotope, dosage form, kit components, dosing schedule)
- claim construction status
- invalidity contentions and evidence
- infringement contentions and comparison charts
What a defensible litigation strength analysis requires
- Independent and dependent claim mappings
- Prior art set for anticipation/obviousness challenges
- Prior art dates relative to filing priority
- Whether the case turns on a narrow technical feature (radiochemical purity spec, chelator identity, linker chemistry, purification steps, sterility assurance, labeling efficiency, in vivo dosing regimen, patient selection criteria)
What does Curium’s likely defense posture look like in a radioisotope patent case?
Answer: Not determinable from the provided record here.
Common defense vectors in radiopharmaceutical IP disputes
- Non-infringement based on differences in:
- labeling chemistry (chelator/linker)
- preparation steps (radiolabeling conditions, purification, formulation buffers)
- stability/quality specifications
- dosing regimen or method-of-use steps
- Invalidity based on:
- prior publications and patents in radionuclide labeling
- obviousness of chelator/linker combinations
- lack of written description or enablement for claimed radioactivity concentration ranges or process parameters
What is the current status of motions, hearings, or scheduling (case timeline)?
Answer: Not determinable from the available record here.
A litigation timeline requires docket entries such as
- Motion to dismiss stage and results
- Markman date and whether claim construction order issued
- Discovery plan, expert disclosures, Daubert motions
- Trial date and any settlement conference outcomes
Could a settlement affect FDA timelines, generic entry, or biosimilar-style design-arounds?
Answer: Not determinable from the provided record here.
Typical settlement impacts that need confirmed deal terms
- License scope (field of use, geography, duration)
- Royalty rate and reporting cadence
- Carve-outs for design-arounds and next-generation products
- Dismissal with or without prejudice
- Court-supervised stipulations on injunction scope
How does this Curium dispute compare with other Advanced Accelerator Applications vs. competitor litigation?
Answer: Not determinable from the provided record here.
Comparison requires
- A list of prior AAAs cases (other defendants)
- Identical asserted patent families and recurring claim themes
- Consistent claim construction outcomes
- Court findings that influence collateral estoppel or inform validity posture
Business risk assessment: what could this case mean for AAAs and Curium?
Answer: Not determinable from the provided record here.
Business levers that require case-specific facts
- Whether the dispute targets the commercial product and blocks an anticipated launch date
- Whether the accused product is at a late FDA stage (approvals, launch readiness, manufacturing transfers)
- Expected damages exposure based on volume, price, and design-around feasibility
- Whether AAAs has a pattern of securing injunctions or only prevailing on damages
Key Takeaways
- A litigation-grade summary of Advanced Accelerator Applications USA, Inc. v. Curium US LLC (1:25-cv-01156) requires docket-specific inputs (complaint, asserted patents, accused product, and remedy requests).
- The available information in this prompt does not include those core litigation facts, so no accurate patent estate, infringement theory, validity analysis, or procedural timeline can be provided.
FAQs
- What court and judge is assigned to Advanced Accelerator Applications USA, Inc. v. Curium US LLC (1:25-cv-01156)?
- Which U.S. patents are asserted in 1:25-cv-01156 and what claim numbers are at issue?
- Is 1:25-cv-01156 tied to an ANDA Paragraph IV notice or another FDA regulatory pathway?
- What remedies are requested (injunction, damages, fees) in the Advanced Accelerator Applications v. Curium case?
- What is the current scheduling status (Markman, discovery, trial date) for 1:25-cv-01156?
References
- Federal court case docket entries for Advanced Accelerator Applications USA, Inc. v. Curium US LLC, Case No. 1:25-cv-01156.
More… ↓
